



56-45 MAIN STREET FLUSHING, N.Y. 11355-5095 718-670-1231

July 7, 1997

CERTIFICATION

Re: Cardiac Ultra-Phase Information Diagnosis (CUPID)

In order to validate the ability of the CUPID system to diagnose heart dysfunction, our hospital established a research protocol #1261096 in September 1996. During the months of September, October and November 1996 we tested 106 patients using the CUPID device. All of those patients were scheduled for angiographic examination.

At the conclusion of the tests, all the hospital records and the angiogram results were sent, with the CUPID diagnostic results, to an independent (FDA approved) monitor for a certification of the results.

The report of the independent monitor, a copy of which is attached, revealed that the CUPID device was compatible with the results of the angiogram in 97 out of 102 cases evaluated, and probably compatible in 2 additional patients. This indicates a 95% accuracy rate when compared with the results of the invasive catheterization. Of course, the CUPID is not able to indicate the location of a coronary artery stenosis, but it is, nevertheless, a very simple, fast, and non-invasive method of assisting the physician in diagnosing the specific disease entity present.

We are confident that CUPID is a significant new method of early screening for heart disease and that it should be used in clinics where cardiac screening is performed, as well as by primary care physicians.

Sincerely,

William J. Tenet, M.D. Medical Director, Cardiovascular Medicine;

Clinical Asst. Professor of Medicine, Cornell Univ. Medical College

Affiliated with The New York Hospital - Cornell Medical Center A member of NYH Care Network, Inc.





56-45 MAIN STREET FLUSHING, N.Y. 11355-5095 718-670-1231

July 7, 1997

CERTIFICATION

Re: Cardiac Ultra-Phase Information Diagnosis (CUPID)

In order to validate the ability of the CUPID system to diagnose heart dysfunction, our hospital established a research protocol #1261096 in September 1996. During the months of September, October and November 1996 we tested 106 patients using the CUPID device. All of those patients were scheduled for angiographic examination.

At the conclusion of the tests, all the hospital records and the angiogram results were sent, with the CUPID diagnostic results, to an independent (FDA approved) monitor for a certification of the results.

The report of the independent monitor, a copy of which is attached, revealed that the CUPID device was compatible with the results of the angiogram in 97 out of 102 cases evaluated, and probably compatible in 2 additional patients. This indicate a 95% accuracy rate when compared with the results of the invasive catheterization. Of course, the CUPID is not able to indicate the location of a coronary artery stenosis, but it is, nevertheless, a very simple, fast, and non-invasive method of assisting the physician in diagnosing the specific disease entity present.

We are confident that CUPID is a significant new method of early screening for heart disease and that it should be used in clinic where cardiac screening is performed, as well as by primary care physicians.

Sincerely.

William J. Tenet, M.D.
Medical Director,
Cardiovascular Medicine;
Clinical Asst. Professor
of Medical Cornell Univ.
Medical College

Affiliated with The New York Hospital Cornell Medical Center A member of NYH Care Network. Inc.



independent Verification of Diagnostic Results of Cardiac Ultra Phase Information Diagnosis "CUPID"

Clinical Trails performed at New York Hospital Medical Center of Queens September through November 1996

Results Section

patient number		
patient number	626	
patient number	002:644	
patient number	1150	
CUPID diagnosis	probably correct	2
patient number	509	
patient number	540	
CUPID diagnosis	probably incorrect	
patient number	597	
patient number	623	
patient number	599:600	

Summary Section

1	Total Tests Performed	106
1	Total Tests Evaluated	102
1	Total Tests Validated Compatible	97
(CUPID % Accuracy Demonstrated	95%

Confidential Report released to Aurogenics, Inc. 030497

172-AURA-9701

Pharmoceutical Consultants, Inc.



